psychedelics biotech firm clearmind medicine inc cmndf cmnd has announced the pricing of its underwritten public offering of 1153847 common shares at a public price of 650 per share for aggregate gross proceeds of 75 million to close on or about november 17 2022 all shares within the offering cannot be sold transferred hypothecated or traded on or through facilities of canadian securities exchange in canada nor for the benefit of a canadian resident until march 17 2023 importantly the current pricing follows a 1for30 reverse stock split made effective on september 30 2022 a financial move we have been seeing quite a lot of recently in direct connection with the offering clearmind’s common shares have been approved for listing on nasdaq and will begin trading in that capital market under the symbol “cmnd” as of november 15 2022 in addition to the offering clearmind has granted aegis capital corp the sole bookrunning manager for the offering a 45day option to purchase up to 173077 additional common shares or 15 of the total shares sold in the offering solely to cover potential overallotments if aegis exercises the option in full for common shares the total gross proceeds of the offering are expected to be approximately 86 million additionally aegis will receive 57692 underwriter warrants each such warrant entitling the agents to receive one common share upon payment of 8125 per share exercisable six months after the start of sales of the offering and expiring on a date no farther than five years after that date